| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 26.1 | 17.1 |
| Gross profit | 21.9 | 13.9 |
| Profit before tax | -6.2 | -13.2 |
| Net income | -6.2 | -13.2 |
| EPS (diluted, $ a share) | $-0.20 | $-0.46 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +53.1% |
|---|---|
| Gross margin | 84.0% |
| Operating margin | -10.1% |
10-Q filed with the SEC, NASDAQ: RCEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Avita Medical, Inc.: key numbers
- Share price
- $15.22Close, Nov 16
- Market cap
- $478M
- Shares outstanding
- 31.42MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Avita Medical, Inc.
All →Avita Medical Debt Financing Update with Perceptive Credit Holdings V, LP
AVITA Medical reported the exercise of warrants by lenders Perceptive Credit Holdings and OrbiMed under existing credit agreements. Both exercises were conducted on a cashless basis, resulting in the issuance of 119,375 and 148,158 shares of common stock, respectively. These transactions represent the settlement of equity obligations tied to previously established debt facilities.
- Counterparty
- Perceptive Credit Holdings V, LP
Avita Medical Financial Results
AVITA Medical reported third quarter 2026 revenue of $26.1 million, a 53% increase year-over-year, driven by growth in its RECELL and Cohealyx products. The company raised its full-year 2026 revenue guidance to $92-$94 million and announced that improved liquidity has alleviated previous 'going concern' doubts. Additionally, the company met revenue milestones to access a final $10 million tranche of its credit facility with Perceptive Advisors.
- Term
- Q3 2026
“AVITA delivered another strong quarter, with revenue increasing 53% year over year and gross margin reaching 84%. RECELL continued to drive our growth, supported by increasing adoption of Cohealyx, while disciplined expense management contributed to a substantial improvement in cash use. Based on our year-to-date performance and continued commercial momentum, we are raising our full-year revenue guidance and remain on track to achieve cash flow breakeven in the fourth quarter.”
Cary Vance, President and Chief Executive Officer of AVITA Medical
“Reaching $85 million in trailing twelve-month revenue reflects the continued execution of our commercial strategy and satisfied the revenue condition required to draw down the remaining $10 million under our credit facility with Perceptive Advisors LLC. This additional, minimally dilutive capital strengthens our liquidity as we advance toward cash flow breakeven and cash generation in the fourth quarter.”
David O'Toole, Chief Financial Officer
Avita Medical Debt Financing Update with Perceptive Credit Holdings V, LP
AVITA Medical disclosed that Perceptive Credit Holdings V, LP exercised a warrant for 500,000 shares of common stock via a cashless exercise. The warrant was originally issued in connection with a January 2026 Credit Agreement and Guaranty. After withholding 112,284 shares for the exercise price, the company issued 387,716 shares to Perceptive on October 28, 2026.
- Counterparty
- Perceptive Credit Holdings V, LP